Alexandria Cole
Family · White Marsh, MDNPI 1669062857
Payments from drug & device makers
Across 236 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$735
- Sanofi$424
- AstraZeneca$404
- Novartis$209
- AbbVie$200
- plus $1K from 18 others
What the payments were for
- Consulting fees$150%
- Food & beverage$4,14695%
- Education$2115%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 62 | $1,100 |
| Regeneron Healthcare Solutions, Inc. | 41 | $735 |
| Sanofi | 24 | $424 |
| AstraZeneca | 22 | $404 |
| Novartis | 11 | $209 |
| AbbVie | 13 | $200 |
| Grifols USA, LLC | 10 | $181 |
| Sanofi-aventis U.S. LLC | 2 | $162 |
| Pfizer | 9 | $162 |
| Kaleo, Inc. | 9 | $158 |
| Optinose US, Inc. | 7 | $131 |
| CSL Behring | 6 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $113 |
| Biocryst US Sales Co., LLC | 3 | $58 |
| Amgen | 2 | $43 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $32 |
| Organon | 1 | $24 |
| Greer Laboratories, Inc. | 1 | $24 |
| Ionis Pharmaceuticals, Inc. | 1 | $20 |
| USWM, LLC | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| ADMA Biomanufacturing LLC | 1 | $15 |
| Alk-abello, Inc | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
How this compares
$4,372 in reported general payments places this provider in the 90th percentile of 2,843 family providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $30,102 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,405 |
| AlvescoCiclesonide | 11 | $3,577 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $1,878 |
| Azelastine Hcl | 69 | $1,845 |
| Olopatadine Hcl | 11 | $1,036 |
| Mometasone Furoate | 12 | $948 |
| Levocetirizine Dihydrochloride | 52 | $806 |
| Fluticasone Propionate | 33 | $444 |
| Famotidine | 51 | $355 |
| Montelukast Sodium | 25 | $188 |
| Triamcinolone Acetonide | 16 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,100 | $30,10241 claims |
| Boehringer IngelheimSpiriva Respimat | $12 | $6,40512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,843 family providers in Maryland.
Other family in White Marsh
- Ariana ChaoLutherville$727K
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
- Sametta SanyaoluFulton$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.